The APAPP Podcast

APAPP

A podcast for Nurse Practitioners and Physician Assistants working in pulmonary, critical care, and sleep medicine with CME credits. 

  1. Oct 29

    Recap of PH Workup for the Non-PH Provider

    Recorded live in Las Vegas, Lori Reed, NP, and Rachel Merling, MSN, APN, AGACNP-BC, FNP-BC, of Pulmonary Associates discuss pulmonary hypertension for general pulmonology and sleep medicine providers. They explain how narrowing and stiffening of the pulmonary arteries increase strain on the right side of the heart, potentially leading to right-sided heart failure, and highlight common warning signs such as unexplained shortness of breath, fatigue, edema, and symptoms that seem out of proportion to COPD or interstitial lung disease. The conversation also reviews key pulmonary hypertension risk factors and diagnostic tools, including echocardiography, BNP or NT-proBNP testing, ventilation-perfusion scans, pulmonary function testing, and right heart catheterization. Through real-world patient cases, Lori and Rachel demonstrate how recognizing subtle symptoms, investigating when treatment is not working as expected, and referring patients early can lead to the right diagnosis, more appropriate treatment, and improved outcomes. Register to join us for the 4th Annual APAPP National Conference in New Orleans in 2027. For more expert-driven pulmonary education, visit the Pulm Hub and APAPP ACE app. Send us Fan Mail Claim your 0.5 CME credits for listening to this episode here: https://forms.gle/42yHmF8UpemVhdDJA Visit our website for more APP Pulmonary, Critical Care, and Sleep Medicine content and free CMEs www.pulmapp.com Follow us on: Instagram @pulmapps Twitter@pulmapp Facebook @association of pulmonary advance practice providers.

  2. Oct 29

    What Are the 3 Key Drivers of Pulmonary Fibrogenesis?

    In this educational video, Leah Fingerman, NP, an interstitial lung disease (ILD) specialist at Emory Pulmonary, explores the three key drivers of pulmonary fibrogenesis and the underlying mechanisms contributing to the development and progression of pulmonary fibrosis. She discusses how repetitive injury to the alveolar epithelium, abnormal fibroblast activation, and genetic predisposition contribute to progressive lung scarring, impaired oxygen exchange, and declining pulmonary function. Leah highlights common environmental risk factors, including cigarette smoking, occupational exposures, air pollution, chronic aspiration, and potential viral triggers, while explaining how persistent fibroblast activation and excessive collagen production create a self-perpetuating cycle of lung fibrosis. She also examines the role of genetic mutations, including MUC5B, TERT, TERC, and other telomere-related genes, in influencing disease susceptibility and progression. With a focus on short telomere syndrome, Leah discusses its association with accelerated forced vital capacity (FVC) decline, poorer clinical outcomes, increased risks associated with immunosuppressive therapy, and complications following lung transplantation. This discussion provides pulmonologists, nurse practitioners, physician assistants, and other healthcare professionals with valuable insights into the pathophysiology of pulmonary fibrosis, genetic risk factors, and the clinical implications of progressive fibrotic interstitial lung disease. Visit the PulmHub for more expert-led pulmonary education and resources designed to support clinical practice. Send us Fan Mail Claim your 0.5 CME credits for listening to this episode here: https://forms.gle/42yHmF8UpemVhdDJA Visit our website for more APP Pulmonary, Critical Care, and Sleep Medicine content and free CMEs www.pulmapp.com Follow us on: Instagram @pulmapps Twitter@pulmapp Facebook @association of pulmonary advance practice providers.

  3. Oct 29

    What unmet needs remain in the diagnosing and treatment of pulmonary fibrosis?

    What unmet needs remain in the diagnosis and treatment of pulmonary fibrosis? In this pulmonary education video, Leah Fingerman, a nurse practitioner at Emory Pulmonary, discusses some of the biggest challenges clinicians face when caring for patients with pulmonary fibrosis and interstitial lung disease (ILD). Many patients are not diagnosed until their disease has already progressed, making earlier detection and intervention a critical unmet need. Leah explores the potential role of improved screening tools, biomarkers, and artificial intelligence (AI) in identifying ILD earlier, predicting disease progression, guiding treatment decisions, monitoring disease activity, and detecting acute exacerbations. She also examines important gaps in pulmonary fibrosis treatment, including the limitations of current antifibrotic therapies, which can slow disease progression but do not reverse existing fibrosis. Looking ahead, new therapies that can repair damaged lung tissue, restore normal lung architecture, and address symptoms could transform care for patients with progressive pulmonary fibrosis. The discussion also highlights the need for better treatments to improve quality of life and reduce the burden of common pulmonary fibrosis symptoms, including chronic cough, shortness of breath (dyspnea), and fatigue. Watch to learn more about the future of pulmonary fibrosis diagnosis, ILD detection, antifibrotic treatment, emerging therapies, and opportunities to improve outcomes for patients living with fibrotic lung disease. Send us Fan Mail Claim your 0.5 CME credits for listening to this episode here: https://forms.gle/42yHmF8UpemVhdDJA Visit our website for more APP Pulmonary, Critical Care, and Sleep Medicine content and free CMEs www.pulmapp.com Follow us on: Instagram @pulmapps Twitter@pulmapp Facebook @association of pulmonary advance practice providers.

  4. Sep 24

    Beyond Spirometry: The Role of FeNO and Methacholine Challenge Testing

    Recorded live at the APAPP Conference in Las Vegas, Brian Bizik, MS, PA-C, DFAAPA, and Heather O’Connell, PA-C, discuss how FeNO testing and methacholine challenge testing can support asthma diagnosis and management when spirometry does not provide a clear answer. They explain how fractional exhaled nitric oxide, or FeNO, offers insight into type 2 airway inflammation and may help clinicians evaluate treatment response, inhaled corticosteroid use, and potential biologic therapy options. The conversation also explores how methacholine challenge testing measures airway hyperresponsiveness and can help confirm or rule out asthma in patients with persistent symptoms but normal or inconclusive spirometry. Brian and Heather review appropriate patient selection, test interpretation, safety considerations, and how these two diagnostic tools can work together to identify different asthma phenotypes, avoid misdiagnosis, and guide more personalized treatment decisions. Register to join us for the 4th Annual APAPP National Conference in New Orleans in 2027. For more expert-driven pulmonary education, visit the Pulm Hub and APAPP ACE app. Send us Fan Mail Claim your 0.5 CME credits for listening to this episode here: https://forms.gle/42yHmF8UpemVhdDJA Visit our website for more APP Pulmonary, Critical Care, and Sleep Medicine content and free CMEs www.pulmapp.com Follow us on: Instagram @pulmapps Twitter@pulmapp Facebook @association of pulmonary advance practice providers.

  5. Sep 24

    FAQ: IPF & PPF What Sets Their Diagnosis Apart

    In this APAPP FAQ, Jessica Glennie, CNP, answers a common question from pulmonary advanced practice providers of what the shared underlying biology of fibrosis is and what are the similarities and key distinctions in how IPF and PPF are diagnosed. Jessica starts by clarifying a frequent point of confusion—idiopathic pulmonary fibrosis is a specific diagnosis under the interstitial lung disease umbrella, while progressive pulmonary fibrosis is not a diagnosis at all, but a behavior seen in fibrotic ILDs other than IPF. Jessica walks through each pathway: diagnosing IPF requires a usual interstitial pneumonia (UIP) pattern on high-resolution CT or biopsy plus a detailed history that excludes drug toxicity, autoimmune disease, and occupational or environmental exposures. Diagnosing PPF applies to patients with an established non-IPF cause—hypersensitivity pneumonitis, silicosis, rheumatoid arthritis, scleroderma, or drug-induced fibrosis—and requires meeting two of three ATS criteria within the past year: worsening respiratory symptoms, physiologic decline (an FVC drop of ≥5% or DLCO drop of ≥10%), or radiologic progression such as increasing honeycombing and traction bronchiectasis. Tune in for key clinical insights on distinguishing IPF from progressive pulmonary fibrosis and applying the criteria in practice.  Register to join us for the 4th Annual APAPP National Conference in New Orleans in 2027. For more expert-driven pulmonary education, visit the Pulm Hub and APAPP ACE app. Send us Fan Mail Claim your 0.5 CME credits for listening to this episode here: https://forms.gle/42yHmF8UpemVhdDJA Visit our website for more APP Pulmonary, Critical Care, and Sleep Medicine content and free CMEs www.pulmapp.com Follow us on: Instagram @pulmapps Twitter@pulmapp Facebook @association of pulmonary advance practice providers.

  6. Sep 24

    Recap of Environment & The Airways

    In this APAPP podcast, Rebecca Ezell, NP, is joined by James McNutt, NP, for a practical discussion on environmental triggers and reactive airway disease. Recapping their 2026 APAPP presentation, Rebecca and James review the global burden of asthma and COPD, the disparities faced by patients in both pollution-heavy urban areas and rural agricultural communities, and how fine particulate matter and diesel exhaust penetrate the airway mucosa to drive oxidative stress, type 2 inflammation, mucus production, and impaired repair pathways. They also share practical strategies pulmonary advanced practice providers can use right away: environmental and occupational exposure screening, HEPA filtration, mask use at work, peak flow journaling to identify exposure patterns, addressing gas stoves, wood smoke, candles, carpet, secondhand smoke, and post-hurricane mold, and writing letters on a patient's behalf for housing accommodations. Tune in for key clinical insights on whole-patient assessment, allergy testing and referral, patient buy-in, and reducing medication burden by controlling the environment. Register to join us for the 4th Annual APAPP National Conference in New Orleans in 2027. For more expert-driven pulmonary education, visit the Pulm Hub and APAPP ACE app. Send us Fan Mail Claim your 0.5 CME credits for listening to this episode here: https://forms.gle/42yHmF8UpemVhdDJA Visit our website for more APP Pulmonary, Critical Care, and Sleep Medicine content and free CMEs www.pulmapp.com Follow us on: Instagram @pulmapps Twitter@pulmapp Facebook @association of pulmonary advance practice providers.

Ratings & Reviews

5
out of 5
13 Ratings

About

A podcast for Nurse Practitioners and Physician Assistants working in pulmonary, critical care, and sleep medicine with CME credits. 

You Might Also Like